DNA Plasmid Therapy Elenagen Shows 90% Success Rate in Treating Chronic Pain in Dogs, Signals Non-Opioid Path for Human Medicine
核心洞察
Elenagen, a novel DNA plasmid therapy encoding the p62 protein (搜索), demonstrated a 90% success rate in reducing chronic osteoarthritis (搜索) pain in dogs during an open-label trial of 17 companion animals.
The therapy works by reprogramming aged mesenchymal stem cells (搜索) to restore their anti-inflammatory function and break the chronic inflammation-pain cycle without using opioids or steroids.
Median pain severity scores dropped from 5.25 to 3.25 and pain interference scores fell from 7.00 to 3.27 by day 70, with no treatment-related adverse events observed.
Elenagen, a novel DNA plasmid therapy previously tested in cancer patients, has demonstrated a 90% success rate in alleviating chronic osteoarthritis (搜索) pain in dogs, offering new hope for non-opioid pain management in both veterinary and human medicine. The peer-reviewed study, published in Frontiers in Veterinary Science, represents a significant breakthrough in addressing chronic pain (搜索) through a disease-modifying approach that targets inflammatory root causes.
Clinical Trial Results Show Dramatic Pain Reduction
In the open-label trial involving 17 dogs aged 4-13 years with severe osteoarthritis (搜索), 90% of animals achieved at least a one-point drop in Pain Severity Score and a two-point drop in Pain Interference Score after ten weekly intramuscular injections of 1 mg Elenagen. The results were striking: median Pain Severity fell from 5.25 to 3.25, while median Pain Interference dropped from 7.00 to 3.27 by day 70.
"These dog data suggest we can help the body to manufacture its own multi-modal anti-inflammatory—without opioids or steroids," said Dr. Alexander Shneider, founder and CEO of CureLab Oncology (搜索). "However, when I think of chronic pain (搜索), I see the faces of war veterans who survived the battlefield but did not survive the opioid addiction back home. While conducting this study, I've been thinking about them."
The therapy demonstrated an excellent safety profile, with no treatment-related adverse events observed and hematology and serum chemistry parameters remaining within normal limits throughout the study period.
Mechanism Targets Stem Cell Dysfunction
Elenagen is a circular DNA plasmid encoding the p62 protein (搜索) that addresses chronic pain (搜索) by targeting a fundamental biological mechanism. Chronic pain affects over 20% of adults worldwide and is increasingly recognized as resulting from both systemic inflammation and dysfunctional mesenchymal stem cells (搜索) (MSCs). In young, healthy individuals, MSCs help regulate inflammation and support tissue repair, but with age and disease, these cells shift toward a pro-inflammatory state and lose their regenerative capacity.
The therapy works by functionally "resetting" aged or dysfunctional MSCs. Upon internalization of the plasmid, these cells regain a youthful phenotype, resuming secretion of anti-inflammatory factors and recovering their ability to differentiate into functional cell types such as osteoblasts rather than adipocytes. Critically, the anti-inflammatory signals produced by Elenagen-reprogrammed MSCs travel over long distances and induce the same beneficial changes in remote MSCs, creating a system-wide amplification cascade.
Functional Improvements Without Structural Changes
The study results supported CureLab's mechanistic hypothesis. After four doses, veterinary assessments, owner reports, and video documentation showed marked reduction in limping and increased activity and playfulness in the treated dogs. By six doses, most dogs exhibited near-complete improvement with limping cessation and return of playful behavior.
Notably, while joint structure remained unchanged, the observed functional improvement suggests that Elenagen targets pain biology directly, offering meaningful relief where structural therapies often fall short. Dogs are considered one of the most clinically relevant translational models for studying chronic pain (搜索) due to their size, natural development of chronic pain conditions such as osteoarthritis (搜索), and shared pathophysiological mechanisms with humans.
Translation to Human Medicine
CureLab Oncology (搜索) developed Elenagen based on previous success in cancer treatment. In clinical testing with platinum-resistant ovarian cancer (搜索) patients, the therapy significantly extended both time to disease progression and overall survival while demonstrating a high safety profile. In collaboration with scientists at Camerino University (搜索) in Italy, the CureLab team analyzed its anticancer mechanisms and demonstrated Elenagen's broad systemic anti-inflammatory effects and ability to restore and modulate MSC function.
This established safety profile from prior human cancer trials significantly de-risks and accelerates the potential development pathway for pain management applications. The company plans larger, placebo-controlled trials in both dogs and humans for 2026.
Implications for Cancer Care
The findings have particular relevance for oncology, where chronic pain (搜索) caused by chemotherapy and other cancer treatments remains a major challenge, limiting both therapeutic options and patients' quality of life. Elenagen's potential to both delay disease progression and extend overall survival while simultaneously reducing chronic pain suggests a highly synergistic therapeutic profile. As a result, CureLab Oncology (搜索) plans to incorporate chronic pain monitoring into its FDA and EMA cancer clinical trials starting in 2026.
The successful validation of this approach may signal a potential paradigm shift toward disease-modifying treatments for chronic pain (搜索) in both veterinary and human medicine, offering an alternative to opioid-based therapies that carry significant risks and often prove ineffective.